IMV‘s immunotherapy DPX-Survivac plus low-dose chemotherapy continues to show sustained benefits in people with heavily treated advanced ovarian cancer, with some benefits lasting up to 16 months, updated findings from a Phase 1/2 clinical trial show. These data “clearly support the relevance of DPX-Survivac as a potential new and much-needed treatment option for advanced recurrent ovarian cancer, a hard-to-treat indication where other immunotherapies have thus far had limited success and where there is a high unmet…
You must be logged in to read/download the full post.
The post DPX-Survivac Responses Now Up to 16 Months in Advanced Ovarian Cancer Trial appeared first on BioNewsFeeds.